Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
FDA Issues Nyxoah an Approvable Letter for its Genio® System
INSIDE INFORMATION REGULATED INFORMATIONFDA Issues Nyxoah an Approvable Letter for its Genio® SystemMont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market...
Nasdaq GlobeNewswire
26/03/2025
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to…
The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility studyThe Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at various locations along the spinal cord to enable restoration of movement and other functions EINDHOVEN, the Netherlands, March26, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation...
Nasdaq GlobeNewswire
26/03/2025
Press Release: Chlamydia vaccine candidate granted fast track designation by the…
Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertilityA phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming daysParis, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi's mRNA vaccine candidate for the prevention of...
Nasdaq GlobeNewswire
26/03/2025
Science! SDU Researchers Identified the Membrane Receptor for Ceramide in…
View original content:https://www.prnewswire.co.uk/news-releases/science-sdu-researchers-identified-the-membrane-receptor-for-ceramide-in-adipocytes-302411537.html View original content: https://www.prnewswire.co.uk/news-releases/science-sdu-researchers-identified-the-membrane-receptor-for-ceramide-in-adipocytes-302411537.html
PR Newswire
26/03/2025
ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient…
Alcon/Santen's ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) Overview Alcon/Santen's ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) Overview ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) 0.02% and 0.005% is a prescription drug used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Its effectiveness is thought to result from the combined action of a Rho kinase...
PR Newswire
25/03/2025
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later than July 10, 2025COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit...
Nasdaq GlobeNewswire
25/03/2025
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2…
/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois. Poster Presentation Details Abstract 3136, “EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance” Session: Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor MicroenvironmentDate and Time: Monday, April 28, 2025, 2:30 PM - 5:00 P.M. CDTLocation: Poster Section 24 ...
Nasdaq GlobeNewswire
25/03/2025
Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine…
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...
Nasdaq GlobeNewswire
25/03/2025
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug…
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profileNew antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March25, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Nasdaq GlobeNewswire
25/03/2025
T-knife Therapeutics Announces Five Presentations at American Association for…
Multiple presentations demonstrate that T-knife's proprietary next-generation technologies address important challenges with current cell therapy constructs, including boosting T cell fitness and persistence within an immunosuppressive tumor microenvironmentTK-6302, a supercharged PRAME T cell therapy, is rapidly advancing towards a Clinical Trial Application (CTA) filing in the fourth quarter of 2025SAN FRANCISCO and BERLIN, March25, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc...
Nasdaq GlobeNewswire
25/03/2025
Skincare Supplement Market to Reach USD 5,857.59 million by 2032, growing at a…
Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/skincare-supplement-market Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/skincare-supplement-market Key Growth Determinants Rising Consumer Awareness and Preference for Preventive Skincare The increasing consumer focus on maintaining healthy skin through nutrition is a key driver...
PR Newswire
25/03/2025
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, March 25, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 24 March 2025,...
Nasdaq GlobeNewswire
25/03/2025
US Vaccines Market worth US$38.44 billion by 2029 with 8.2% CAGR |…
Browse in-depth TOC on "US Vaccines Market" Browse in-depth TOC on "US Vaccines Market" 151 - Tables 57 - Figures By Based on technology,the US vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. In 2023, conjugate vaccine segment dominated the US vaccine market. Rising awareness and preventive healthcare...
PR Newswire
25/03/2025
Hubble Therapeutics closes Series A Financing to develop gene therapy cure for…
"For over the past 20 years, my lab has developed in vitro and in vivo models of ion channelopathy to develop curative gene therapies for several devastating pediatric blindness diseases," Dr. Bikash Pattnaik, professor in the Departments of Pediatrics, Ophthalmology and Visual Science at the University of Wisconsin–Madison, Daniel M. Albert Chair McPherson Eye Research Institute and scientific co-founder of Hubble Therapeutics LLC, "The development of the HUB-101 gene therapy for…
PR Newswire
25/03/2025
Drug Discovery Services Market worth US$27.23 billion in 2030 with 10.7% CAGR |…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129 Browse in-depth TOC on "Drug Discovery Services Market" 120 - Tables60 - Figures200 - Pages By Based on Chemistry Services Segment,the market is segmented by type into chemistry services, and biology services. The chemistry services segment dominated the market in 2024. The chemistry...
PR Newswire
25/03/2025
Hormonal Contraceptive Market to Reach $26.6 Billion, Globally By 2035 at 3.6%…
In addition, government initiatives promoting contraception and rise in preference for long-acting reversible contraceptives contribute to market expansion. In addition, government initiatives promoting contraception and rise in preference for long-acting reversible contraceptives contribute to market expansion. Request Sample of the Report on Global Hormonal Contraceptive Market 2035 -https://www.alliedmarketresearch.com/request-sample/4574 Prime Determinants of Growth The...
PR Newswire
25/03/2025
PioCreat 3D Showcases Cutting-Edge Dental 3D Printing Solutions at IDS 2025
Key Highlights at PioCreat 3D's Booth Key Highlights at PioCreat 3D's Booth Cutting-Edge Dental 3D Printers: DJ89PLUS: An8KLCD 3D printer with 29μm precision, heating chamber, and stable performance for dental applications. D158: A compact DLP 3D printer with 62μm precision, automatic lifting cover, and stable Z-axis, designed for reliable and efficient dental printing. DJ68: Features a 6.8″9KLCD screen with 8520 x 4320 resolution and 18µm XY-axis accuracy, ideal for...
PR Newswire
25/03/2025
Kolmar Korea Develops World's First Hybrid Composite Sunscreen, Leading the…
Sunscreens are classified into organic and inorganic types based on their UV protection mechanisms. Organic sunscreens absorb and convert UV rays into heat energy, offering smooth application and reduced white cast. Conversely, inorganic sunscreens reflect UV rays from the skin, providing strong UV protection but often leaving a white cast. Hybrid sunscreens combine these mechanisms to maximize benefits, though technical challenges such as ingredient aggregation have hindered achieving optimal…
PR Newswire
25/03/2025
PHARMANUTRA S.P.A.: SUCROSOMIAL IRON® MENTIONED IN THE GUIDELINES OF THE "WORLD…
The Guidance, which focuses on the efficiency and improvement of patient management in order to reduce the use of blood transfusions, is the result of extensive collaboration between international experts in multidisciplinary fields dedicated to improving patient outcomes, safety and quality of care. It is therefore also a useful practical guide to address the global problem of iron deficiency and anaemia, blood loss and coagulopathies with bleeding. The Guidance, which focuses on the...
PR Newswire
25/03/2025
Roche Annual General Meeting 2025
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed38th consecutive dividend increase to CHF 9.70 per share Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders in attendance, who represented 77...
Nasdaq GlobeNewswire
25/03/2025
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab…
TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other centers are currently enrolling include Johns Hopkins,...
Nasdaq GlobeNewswire
25/03/2025
EQT Foundation opens global grant program for scientists working on solutions…
EQT Foundation's Breakthrough Science grants program is designed to fund scientists working on solutions at the intersection of science and commercialization. It prioritizes research focused on: EQT Foundation's Breakthrough Science grants program is designed to fund scientists working on solutions at the intersection of science and commercialization. It prioritizes research focused on: Beyond funding, EQT Foundation provides access to EQT's global network, connecting scientists with...
PR Newswire
25/03/2025
Besmile at IDS 2025: Unleashing 24/7 Unmanned Milling Machine and Next Gen…
Aconia 3D Master, Besmile's multilayered zirconia, offers exceptional strength (1,200 MPa) and natural aesthetics. Its unique structure mimics the colour gradient of human teeth, providing restorations that are both durable and beautiful, reducing the chance of rework and boosting productivity. Aconia 3D Master, Besmile's multilayered zirconia, offers exceptional strength (1,200 MPa) and natural aesthetics. Its unique structure mimics the colour gradient of human teeth, providing restorations...
PR Newswire
25/03/2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active…
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipelineLausanne, Switzerland, March 25, 2025– AC...
Nasdaq GlobeNewswire
25/03/2025
Altri Comunicati
